Research Article

Ligustrazine inhibits the proliferation and migration of ovarian cancer cells via regulating miR-211

Hairong Zhang1, Shichao Ding2,3 and Lei Xia4

1Department of Obstetrics and Gynecology, Shandong Provincial Third Hospital, Cheelpo College of Medicine, Shandong University, Jinan 250031, China; 2Department of Internal Medicine, The Third Affiliated Hospital of Shandong Medical University, Jinan 250031, China; 3Department of Internal Medicine, Affiliated Hospital of Shandong Academy of Medical Sciences, Jinan 250031, China; 4Department of Pathology, Shandong University of Traditional Chinese Medicine, Jinan 250355, China

Correspondence: Lei Xia (xialei@sdutcm.edu.cn)

Introduction

Ovarian cancer (OC) is a commonly diagnosed female cancer [1–3]. Like most types of cancer, OC lacks clinical symptoms at its early stages, therefore, most patients have proceeded to the advanced stage at the time of diagnosis [4–6]. Moreover, the pathogenesis of OC remains unclear, and there are no specific therapies for OC, leading to an adverse prognosis of the disease [7–9]. Thus, it is of great importance to develop new therapeutic strategies to improve the therapeutic efficacy of OC and to increase the 5-year survival rate of OC patients.

In recent years, the role of traditional medicines as alternative therapeutic methods for the treatment of cancers has been evaluated in many studies [10,11]. Ligustrazine (LSZ) is an active component used in Traditional Chinese Medicine extracted from the rhizome of *Ligusticum wallichii*. Previous studies have suggested that LSZ can exert anti-inflammatory, anti-fibrotic, and anti-oxidant activities. In some recent studies, a tumor suppressive activity of LSZ has been described for several cancers, including lung cancer, gastric cancer, breast cancer, and melanoma [10–16].

MicroRNAs (miRNAs) are a class of single-stranded RNAs. Unlike messenger RNAs (mRNA), miRNAs are not translated into a protein, although they can bind to the 3′-UTR of their target mRNAs and can
Figure 1. Cell viability and proliferation ability following treatment with different concentrations of LSZ
SK-OV-3 and OVCAR-3 cells were treated with different concentrations of LSZ and the cell viability (A) and proliferation (B) were evaluated by CCK-8 and colony formation assays, respectively, after incubation. *P < 0.05, **P < 0.01, ***P < 0.001.

epigenetically inhibit the expression of their target genes [17,18]. Over the past few decades, the roles of miRNAs in different types of cancers, including OC, have been extensively investigated [19,20], and several miRNAs have been identified as potential therapeutic targets for the treatment of OC [21–24].

LSZ has been reported to exert its anti-tumor effects by inhibiting the growth, migration, and epithelial–mesenchymal transition (EMT) of different types of cancer cells, including OC [10,25,26]. On the other hand, LSZ has been reported to regulate cellular activities through its effects on the expression of several miRNAs [26,27]. MicroRNA-211 (MiR-211) is considered a tumor suppressor in the pathogenesis of OC, however, whether LSZ regulates the expression of miR-211, and thus contributes to its anti-tumor activity in the pathogenesis of OC remains to be explored. In the present study, our aim was to explore the effects of LSZ on the migration, invasion, and EMT of OC cells. The roles played by miR-211 during these processes was also investigated.

Materials and methods
Cell lines and treatment
The human OC line SK-OV-3 and OVCAR-3 were purchased from ATCC (Manassas, VA, U.S.A.). Cells were cultured in RPMI-1640 medium (Gibco, CA, U.S.A.) containing 10% fetal bovine serum (Gibco), with 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco). Cells were cultured in an incubator at 37°C, and supplied with 5% CO₂. To determine the effects of LSZ on the behavior of SK-OV-3 cells, cells were treated with 0, 0.5, 1, and 2 mM LSZ at different time points (Sigma–Aldrich Corp., St. Louis, MO, U.S.A.).
Figure 2. Cell migration and invasion ability following treatment with different concentrations of LSZ

SK-OV-3 and OVCAR-3 cells were treated with different concentrations of LSZ and the migration (A) and invasion (B) were evaluated by wound healing scratch and transwell assays, respectively, after incubation. *P<0.05, **P<0.01, ***P<0.001.

Transfection

To explore the role of miR-211 in LSZ-induced effects on SK-OV-3 and OVCAR-3 cells, cells were seeded on to 24-well plates and randomly divided into the following groups: blank control group, LSZ group (cells treated with 1 mM LSZ), LSZ+miR-211 inhibitor group (cells treated with 1 mM LSZ), and the ginsenoside-Rg3+ HOTAIR control group. Cells were transfected with the miR-211 inhibitor in a 2.5 µl volume of Lipofectamine 2000 (Invitrogen, U.S.A.). Experiments were performed in triplicate.

CCK-8 cell viability assay

Cell viability was determined using the CCK-8 cell viability assay. Briefly, cells were seeded on to a 96-well plate and the CCK-8 solution (purchased from Beyotime, Shanghai, China) was added to the wells (10 µl/well) and incubated
Figure 3. Increased expression of miR-211 by LSZ

Expression of miR-211 in SK-OV-3 (A) and OVCAR-3 (B) cells exposed to different concentrations of LSZ was evaluated by qRT-PCR. (C) Effects of miR-211 inhibitor on the expression of miR-211 in SK-OV-3 cells. (D) Effects of miR-211 inhibitor on the expression of miR-211 in LSZ-treated SK-OV-3 cells. \( *P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001 \). Expression of miR-211 was normalized to the expression of U6.

at 37°C for 2 h. Next, the optical density (OD) value was measured at the wavelength of 450 nm using a microplate reader (Bio-Rad, Hercules, CA, U.S.A.) to evaluate the viability of the cells at different treatment concentrations.

Colony formation assay

Colony formation assay was performed to determine the proliferation ability of SK-OV-3 and OVCAR-3 cells. Briefly, cells were cultured for 10 days, fixed in methanol, and then stained by Crystal Violet (0.1%). Colonies (diameter $\geq$ 100 μm) were counted microscopically.
Figure 4. Inhibition of cell viability and proliferation by LSZ by regulating miR-211 expression
Cell viability was determined using the CCK-8 (A) and colony formation (B) assay after exposure to different treatments. *P<0.05, **P<0.01, ***P<0.001.

Quantitative real-time polymerase chain reaction
The expression of miR-211 was determined using quantitative real-time polymerase chain reaction (qRT-PCR). RNeasy Mini Kit (Qiagen, Germany) was utilized to isolate RNA according to the manufacturer’s protocol and the concentration of RNA was identified by a spectrophotometer Nanodrop 2000 (Thermo Fisher Scientific, U.S.A.). The M-MLV was applied to synthesize cDNA through reverse transcription. PrimeScript™ RT-PCR Kit (TaKaRa, Japan) was used for RT-PCR. For cDNA synthesis, samples were incubated at 43°C for 30 min, 97°C for 5 min, and 5°C for 5 min. The thermal cycling parameters were as follows: 95°C for 5 min followed by 40 cycles of 95°C for 30 s, 59°C for 30 s, 72°C for 30 s. GAPDH was regarded as an internal control. Each experiment was performed in triplicate. The abundance of gene expression was determined by $2^{-\Delta\Delta C_t}$ relative quantification [18].

Western blotting
Western blotting was used to assess protein expression. Cells were lysed in RIPA buffer (Thermo Fisher Scientific, U.S.A.) and the total protein concentration was verified by the BCA Kit (Thermo Fisher Scientific, U.S.A.). A total of 20 μg of proteins were separated by gel electrophoresis (15% SDS/PAGE) and then transferred to PVDF membrane (Millipore, Netherlands). The membrane was blocked with 5% skimmed milk for 2 h. Subsequently, the primary antibodies were incubated for 1 h at room temperature. Next, the membrane was incubated with the relative secondary antibody (ab6721, 1:2000, Abcam, U.S.A.) conjugated with HRP for 45 min at room temperature. Then, the ECL Western Blotting Kit (Santa Cruz Biotechnology, Inc.) was used for membrane staining and the results were analyzed with ImageJ software. Each experiment was performed in triplicate.
Figure 5. Inhibition of cell migration and invasion ability by LSZ by regulating miR-211 expression

(A) The cell migration was determined by the wound healing assay after different treatments. (B) The cell invasion was determined by the transwell assay after different treatments. *P < 0.05, **P < 0.01.

Scratch-wound healing assay
The scratch-wound healing assay was employed to evaluate the migration and invasion ability of SK-OV-3 and OVCAR-3 cells. Cells were seeded into 96-well plates and a monolayer cell culture was obtained. Next, a new 1-ml pipette tip was used to generate a scratch across the center of the wells. Therefore, the width of the scratch was defined by the outer diameter of the tip. The cells were then incubated at 37°C with 5% CO₂ for 72 h. The migrated cells were captured by microscope (Olympus, Tokyo, Japan).

Transwell cell invasion assay
SK-OV-3 and OVCAR-3 cells were seeded on to the upper chamber of the transwell pre-coated with Matrigel (BD Biosciences) and incubated for 24 h. Next, the invaded cells were fixed by paraformaldehyde (4%) and then stained by 0.1% Crystal Violet and imaged by a microscope.
Figure 6. Inhibition of EMT by LSZ by regulating miR-211 expression
The EMT of the cells was determined by Western blotting after different treatments.

Statistical analysis
All data are presented as the mean ± standard deviation (SD) and were analyzed using GraphPad Prism version 7.0 (GraphPad Software, La Jolla, CA, U.S.A.). Moreover, the Student's t test and one-way analysis of variance was employed for data comparison. A P-value <0.05 was regarded as a significant statistical difference.

Results
LSZ inhibited viability and proliferation of SK-OV-3 and OVCAR-3 cells
We first examined the effects of LSZ on the viability and proliferation ability of SK-OV-3 and OVCAR-3 cells by CCK-8 and colony formation assays. LSZ treatment markedly inhibited the viability of the cells (at 24 and 48 h, Figure 1A, P <0.05 and P <0.01, respectively) and the potential for cell proliferation (Figure 1B, P <0.01) of SK-OV-3 and OVCAR-3 cells in a dose-dependent manner. The intermediate concentration of 1 mM LSZ was used for the subsequent experiments.

LSZ inhibited migration and invasion of SK-OV-3 and OVCAR-3 cells
We further examined the effects of LSZ on the migration and invasion ability of SK-OV-3 and OVCAR-3 cells by scratch and transwell assays. As Figure 2 shows, LSZ treatment markedly inhibited the migration and invasion ability of SK-OV-3 and OVCAR-3 cells in a dose-dependent manner (P <0.01).

LSZ increased the expression of miR-211 in SK-OV-3 and OVCAR-3 cells
The expression of miR-211 was significantly increased in SK-OV-3 and OVCAR-3 cells following treatment with LSZ (Figure 3A,B). Thus, we explored whether miR-211 expression could be regulated by the presence of miR-211 inhibitors in 1 mM LSZ-treated SK-OV-3 cells. As shown in Figure 3C, 48 h after transfection, miR-211 inhibitors markedly decreased the levels of miR-211 in SK-OV-3 cells in comparison with the miR-211 negative control (NC)-treated cells, suggesting that transfection had been successfully performed; moreover, in the LSZ+miR-211 inhibitor treatment group, the level of miR-211 significantly decreased compared with LSZ treatment alone (Figure 3D, P <0.01).

LSZ inhibited viability of SK-OV-3 cells by regulating the expression of miR-211
Next, the effects of miR-211 on the viability and proliferation of LSZ-treated SK-OV-3 cells were determined using the CCK-8 cell viability and colony formation assays. We found that the miR-211 inhibitor partially abrogated the
LSZ-induced anti-tumor effects by increasing the cell viability and proliferation ability of LSZ-treated SK-OV-3 cells (Figure 4, \( P < 0.01 \)).

**LSZ inhibited migration and invasion ability of SK-OV-3 cells by regulating the expression of miR-211**

The effects of miR-211 on the migration and invasion ability of LSZ-treated SK-OV-3 cells were determined using the wound healing assay and transwell assay. As shown in Figure 5, LSZ significantly inhibited the migration (Figure 5A) and invasion (Figure 5B) of SK-OV-3 cells, and the transfection of miR-211 inhibitor led to increased migration of LSZ-treated SK-OV-3 cells (\( P < 0.01 \)).

**LSZ inhibited EMT of SK-OV-3 cells by regulating the expression of miR-211**

Finally, the effects of miR-211 on the EMT of LSZ-treated SK-OV-3 cells were examined. The expression of EMT markers was examined by the Western blotting assay. LSZ increased the expression of the epithelial markers E-cadherin and \( \beta \)-catenin and decreased the expression of the mesenchymal markers N-cadherin and vimentin. Conversely, transfection of the miR-211 inhibitor partially blocked the LSZ-induced anti-EMT effects by increasing the expression of E-cadherin and decreasing the expression of N-cadherin and vimentin in SK-OV-3 cells (Figure 6).

**Discussion**

In the present study, we evaluated the tumor suppressive roles of LSZ in an *in vitro* model of OC and investigated the related mechanism involved. We found that LSZ inhibited the proliferation, migration, invasion, and EMT of the OC cell line SK-OV-3 cells by regulating the expression of miR-211.

The tumor suppressive roles of LSZ have been discussed in several previous studies [10,11,27]. Yin et al. suggested that LSZ inhibits both migration and invasion [28], but not the numbers of SK-OV-3 and OVCAR-3 cells after a 24-h treatment. In the present study, we found that LSZ decreased the migration ability of SK-OV-3 cells at 24 h in a dose-dependent manner, which was consistent with the observation by Yin et al. [28]. Moreover, we also observed that LSZ did not exert a significant effect on the viability of SK-OV-3 and OVCAR-3 cells at 24 h, which was also consistent with Yin et al.’s findings, although when the culture time was extended to 48 h, we found that LSZ decreased the cell viability in a dose-dependent manner [28]. The above results suggested that LSZ inhibited the oncogenic behavior of OC cells *in vitro*. However, the underlying mechanism still requires further investigation.

LSZ has been reported to affect the expression of miRNAs in different cell contexts in order to exert its biological activity. MiR-211 is considered a tumor suppressor in OC [27], and our finds show that miR-211 was up-regulated in LSZ-treated SK-OV-3 cells, and more importantly, transfection of a miR-211 inhibitor in LSZ-treated SK-OV-3 cells partially blocked the anti-tumor behavior of LSZ by increasing the viability, proliferation, and migration of the cells. Taken together, these results demonstrated the involvement of miR-211 in LSZ-induced anti-tumor effects, suggesting that LSZ may inhibit the growth and metastatic potential of OC cells by increasing the expression of miR-211.

EMT is considered an important cellular event during the progression of tumor metastasis [20,23]. It has been reported that LSZ could inhibit EMT in different types of cancer cells. Furthermore, miR-211 has also been found to inhibit the EMT of tumor cells. In our study, we found that LSZ increased the expression of the epithelial marker E-cadherin and decreased the expression of the mesenchymal markers N-cadherin and vimentin. Conversely, transfection of miR-211 inhibitor partially blocked LSZ-induced anti-EMT effects by increasing the expression of E-cadherin and decreasing the expression of N-cadherin and vimentin in SK-OV-3 cells. Our results suggested that LSZ inhibits the EMT of SK-OV-3 cells by regulating the expression of miR-211.

In conclusion, the present study revealed that LSZ may function as a tumor suppressor in OC; LSZ may exert its anti-tumor activity by increasing the expression of miR-211. Although further clinical and *in vivo* animal studies are still required to strengthen our conclusion, the present study may provide the theoretical basis for the potential application of LSZ as an alternative therapeutic strategy for the treatment of OC.

**Data Availability**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Competing Interests**

The authors declare that there are no competing interests associated with the manuscript.
Funding
This work was supported by the National Natural Science Foundation of China [grant number 81673779]; and the Key R&D Projects in Shandong Province [grant number 2016CYJS08A01-3].

Author Contribution
Hairong Zhang performed most of the experiments. Shichao Ding performed some of the experiments and the statistical analysis. Lei Xia designed the study, wrote the manuscript, and provided the funding for the present study.

Abbreviations
CCK-8, cell counting kit-8; EMT, epithelial–mesenchymal transition; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; LSZ, Ligustrazine; miRNA, microRNA; miR-211, microRNA-211; M-MLV, moloney-murine leukemia virus; mRNA, messenger RNA; OC, ovarian cancer.

References
1 Kuryk, L. and Moller, A.W. (2020) Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor. J. Med. Virol. 92, 1309–1315, https://doi.org/10.1002/jmv.25677
2 Printz, C. (2020) Study finds that women with posttraumatic stress disorder have an increased risk of ovarian cancer. Cancer 126, 468–469, https://doi.org/10.1002/cncr.32706
3 Zhong, H., Chen, H., Qiu, H., Huang, C. and Wu, Z. (2020) A multomics comparison between endometrial cancer and serous ovarian cancer. PeerJ 8, e8347, https://doi.org/10.7717/peerj.8347
4 Li, X., Qin, S., Mo, Z. et al. (2020) CircRNA_100395 inhibits cell proliferation and metastasis in ovarian cancer via regulating miR-1228b/p53 epithelial–mesenchymal transition (EMT) axis. J. Cancer 11, 599–609, https://doi.org/10.7150/jca.39541
5 Maniati, E., Berlato, C., Gopinathan, G. et al. (2020) Mouse ovarian cancer models recapitulate the human tumor microenvironment and patient response to treatment. Cell Rep. 30, 525.e527–540.e527, https://doi.org/10.1016/j.celrep.2019.12.034
6 Kovac, E., Carlsson, S.V., Ljila, H. et al. (2020) Association of baseline prostate-specific antigen level with long-term diagnosis of clinically significant prostate cancer among patients aged 55 to 60 years: a secondary analysis of a cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Jama Netw. Open 3, e191284, https://doi.org/10.1001/jamanetworkopen.2019.19264
7 Padmanabhan, S., Zou, Y. and Vancurova, I. (2020) Flow cytometry analysis of surface PD-L1 expression induced by IFNgamma and Romidepsin in ovarian cancer cells. Methods Mol. Biol. 2108, 221–228, https://doi.org/10.1007/978-1-0716-0247-8_19
8 Padmanabhan, S., Zou, Y. and Vancurova, I. (2020) Immunoblotting analysis of intracellular PD-L1 levels in interferon-gamma-treated ovarian cancer cells stably transfected with Bcl3 shRNA. Methods Mol. Biol. 2108, 211–220, https://doi.org/10.1007/978-1-0716-0247-8_18
9 Zhang, S., Cheng, J., Quan, C. et al. (2019) circECLSR1 (hsa_circ_0063809) contributes to paclitaxel resistance of ovarian cancer cells by regulating FOXR2 expression via miR-1252. Mol. Ther. Nucleic Acids 19, 718–730, https://doi.org/10.1016/j.omtn.2019.12.005
10 Pan, J., Shang, J.F., Jiang, G.Q. and Yang, Z.X. (2015) Ligustrazine induces apoptosis of breast cancer cells in vitro and in vivo. J. Cancer Res. Ther. 11, 454–458, https://doi.org/10.4103/0973-1482.147378
11 Chen, J., Wang, W., Wang, H., Liu, X. and Guo, X. (2014) Combination treatment of ligustrazine piperezin derivate DLJ14 and adriamycin inhibits progression of resistant breast cancer through inhibition of the EGF/Pi3K/Akt survival pathway and induction of apoptosis. Drug Discov. Ther. 8, 33–41, https://doi.org/10.5552/dtt.8.33
12 Xie, H.J., Zhao, J., Zhuo-Ma, D., Zhan-Dui, N., Er-Bu, A. and Tsering, T. (2019) Inhibiting tumour metastasis by DQA modified paclitaxel plus ligustrazine micelles in treatment of non-small-cell lung cancer. Artif. Cells Nanomed. Biotechnol. 47, 3465–3477, https://doi.org/10.1080/21691401.2019.1653900
13 Zou, Y., Zhao, D., Yan, C. et al. (2018) Novel ligustrazine-based analogs of piperlongumine potently suppress proliferation and metastasis of colorectal cancer cells in vitro and in vivo. J. Med. Chem. 61, 1821–1832, https://doi.org/10.1021/acs.jmedchem.7b01086
14 Cheng, L., Ma, H., Shao, M. et al. (2017) Synthesis of folatechitosan nanoparticles loaded with ligustrazine to target folate receptor positive cancer cells. Mol. Rep. 16, 1101–1108, https://doi.org/10.3982/embr.2017.6740
15 Zha, G.F., Qin, H.L., Youssif, B.G.M. et al. (2017) Discovery of potential anticancer multi-targeted ligustrazine based cyclohexanone and oxime analogs overcoming the cancer multidrug resistance. Eur. J. Med. Chem. 135, 34–48, https://doi.org/10.1016/j.ejmech.2017.04.025
16 Ai, Y., Zhu, B., Ren, C. et al. (2016) Discovery of new monocarbonyl Ligustrazine-Curcumin hybrids for intervention of drug-sensitive and drug-resistant lung cancer. J. Med. Chem. 59, 1747–1760, https://doi.org/10.1021/acs.jmedchem.5b01203
17 Zhou, X., Chen, J., Zhang, H., Chen, X. and Shao, G. (2018) MicroRNA-23b attenuates the H2O2-induced injury of microglial cells via TAB3/NF-kappaB signaling pathway. Int. J. Clin. Exp. Pathol. 11, 5765–5773
18 Han, J., Li, Y., Zheng, H. et al. (2018) MicroRNA-142-5p facilitates the pathogenesis of ulcerative colitis by regulating SOCS1. Int. J. Clin. Exp. Pathol. 11, 5735–5744
19 Zhu, M., Li, Y. and Sun, K. (2018) MicroRNA-182-5p inhibits inflammation in LPS-treated RAW264.7 cells by mediating the TLR4/NF-kappaB signaling pathway. Int. J. Clin. Exp. Pathol. 11, 5725–5734
20 Huang, Y. and Yang, N. (2018) MicroRNA-20a-5p inhibits epithelial to mesenchymal transition and invasion of endometrial cancer cells by targeting STAT3. Int. J. Clin. Exp. Pathol. 11, 5715–5724

C⃝ 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
21 Xue, F., Li, Q.R., Xu, Y.H. and Zhou, H.B. (2019) MicroRNA-139-3p inhibits the growth and metastasis of ovarian cancer by inhibiting ELAVL1. *Onco Targets Ther.* **12**, 8935–8945, https://doi.org/10.2147/OTT.S210739

22 Buranjiang, G., Kuerban, R., Abuduwanke, A., Li, X. and Kuerban, G. (2019) MicroRNA-331-3p inhibits proliferation and metastasis of ovarian cancer by targeting RCC2. *Arch. Med. Sci.* **15**, 1520–1529, https://doi.org/10.5114/ams.2018.77858

23 Wang, L., Zhao, F., Xiao, Z. and Yao, L. (2019) Exosomal microRNA-205 is involved in proliferation, migration, invasion, and apoptosis of ovarian cancer cells via regulating VEGFA. *Cancer Cell Int.* **19**, 281, https://doi.org/10.1186/s12935-019-0990-z

24 Liu, F., Zhao, H., Gong, L., Yao, L., Li, Y. and Zhang, W. (2018) MicroRNA-129-3p functions as a tumor suppressor in serous ovarian cancer by targeting BZW1. *Int. J. Clin. Exp. Pathol.* **11**, 5901–5908

25 Avila-Carrasco, L., Majano, P., Sanchez-Tomero, J.A. et al. (2019) Natural plants compounds as modulators of epithelial-to-mesenchymal transition. *Front. Pharmacol.* **10**, 715, https://doi.org/10.3389/fphar.2019.00715

26 Wei, S. and Wang, H. (2019) Ligustrazine promoted hypoxia-treated cell growth by upregulation of miR-135b in human umbilical vein endothelial cells. *Exp. Mol. Pathol.* **106**, 102–108, https://doi.org/10.1016/j.yexmp.2018.12.005

27 Xu, D., Chi, G., Zhao, C. and Li, D. (2018) Ligustrazine inhibits growth, migration and invasion of medulloblastoma Daoy cells by up-regulation of miR-211. *Cell. Physiol. Biochem.* **49**, 2012–2021, https://doi.org/10.1159/000493712

28 Yin, J., Yu, C., Yang, Z. et al. (2011) Tetramethylpyrazine inhibits migration of SKOV3 human ovarian carcinoma cells and decreases the expression of interleukin-8 via the ERK1/2, p38 and AP-1 signaling pathways. *Oncol. Rep.* **26**, 671–679